Welcome to Gyre Therapeutics
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
More news
